The world stent market - on track for $2 billion by 2000
This article was originally published in Clinica
Executive Summary
The world stent market may be worth $692 million in 1995 and as much as $2,237 million by the year 2000, a Hambrecht & Quist industry report estimates. In the US alone, stent revenues this year are estimated to total $534 million, 369% more than last year. They are predicted to reach $1,522 million by 2000. The US represents the largest potential market, and by the beginning of the next century, when stents could be used in 75% of interventional procedures, may account for about 68% of world stent revenues.
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.